Progeria effort pays off

Credit: COURTESY OF JOHN HURLEY FOR THE PROGERIA RESEARCH FOUNDATION" /> Credit: COURTESY OF JOHN HURLEY FOR THE PROGERIA RESEARCH FOUNDATIONLeslie Gordon's son Sam was 22 months old when he was diagnosed with Hutchinson-Gilford Progeria syndrome, a devastating disease in which children age rapidly and usually die between their 7th and 20th birthdays. Gordon, an MD/PhD, and her MD husband, Scott Berns, discovered an astonishing void of information on the disease, which is so rare that it

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Leslie Gordon's son Sam was 22 months old when he was diagnosed with Hutchinson-Gilford Progeria syndrome, a devastating disease in which children age rapidly and usually die between their 7th and 20th birthdays. Gordon, an MD/PhD, and her MD husband, Scott Berns, discovered an astonishing void of information on the disease, which is so rare that it affects only 1 in 4-8 million live births. "There was nothing," says Gordon. "There were no more than 100 publications in total throughout history. There had never been any NIH funding, there were three to four scientists in the world studying it, and there was no active research program."

For lack of existing organizations, they founded their own, the Progeria Research Foundation. They created a cell and tissue bank, and raised enough money to give out fifteen $100,000 research grants to date. A clinical and research database with information on more than 40 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Ivan Oransky

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide